The American Journal of Managed Care11h
Upadacitinib May Induce Alopecia Areata in Patients With AD
Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.
The American Journal of Managed Care14h
The Burden of AD Flares and Impact of Ruxolitinib Initiation on Utilization of Other Therapies
Posters at AMCP Nexus analyzed the burden of flares on patients with atopic dermatitis (AD) and the impact initiating ...
Medscape17h
Ruxolitinib Cream Shows Promise in Treating Lichen Planus
A study of ruxolitinib cream in patients with lichen planus indicated that the topical JAK inhibitor is a promising potential ...
The Happy Body Project on MSN17h
Rosemary Scalp Scrub
Taking care of your scalp is just as important as caring for your hair, and what better way to do it than with an all-natural ...
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two ...
The Bakersfield Californian18h
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic ...
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1Second approval of ZORYVE outside of the United ...